Biotechnology, Pharmaceutical and Life Science Reports and Courses

Main Pages

Best Selling Products

BioNewsCast Press Release Distribution Service

Vaccine Technology 2009 Conference

Veterinary Diagnostics Markets

Practical Guide to Finding Partners in Pharma & Biotech, 2nd edition

Royalty Financing Agreements in Pharma, Biotech and Diagnostics

New Products

Attention Deficit Hyperactivity Disorder: Diagnosis and Treatment

Bioinformatics Market Potential

Biotechnology in the European Union; Trends, Investing & Country Profiles

China Pharmaceutical Industry: Analysis and Market Trends

European Generic Drug Market Potential

Global Biotechnology Markets Trends

Strategic Alliances in World Pharma and Biotech Markets

Understanding China's Chemical Industry

Understanding Genomics and Global Health Impacts

Understanding Pharmacogenomics

BioPortfolio | Datamonitor Healthcare Reports | Commercial Insight: Rheumatoid arthritis - Anti-TNFs defend first-line biologic position despite competition

Commercial Insight: Rheumatoid arthritis - Anti-TNFs defend first-line biologic position despite competition

Datamonitor forecasts that total sales for the seven major rheumatoid arthritis markets will grow from $7 billion in 2007 to over $12 billion in 2017. The sustained uptake of anti-TNFs combined with the launch of several new biologic products will drive growth in the short-and mid-term. However, biosimilar entry will cause a small contraction in market value at the end of the forecast period.

Scope

*In-depth analysis of the current and future rheumatoid arthritis market across the US, 5EU and Japanese markets, and a 'rest of world' snapshot.

*Rheumatoid arthritis sales forecasts for over 20 key brands to 2017, and total brand figure to benchmark indication-specific sales

*Provides detailed brand analysis, including discussion of all anti-TNFs and impact of alternative biologic products like Actemra

*Assess the strategies of several key developers in the rheumatoid arthritis market

Highlights

Simponi (golimumab) exemplifies a brand adopting both follow-on and dual formulation strategies, but positioning with Remicade will be challenging. Careful brand management, sales and marketing efforts and a well executed switching strategy will see Simponi achieve blockbuster status in the seven major markets.

The TNF-failure pool will increase considerably as patients cycle through a maximum of 2-3 TNF therapies. Currently, Orencia and Rituxan/MabThera compete in this sub-population, which will become increasingly crowded. With its well-perceived safety profile and Actemra's US approval delay, Orencia will cement its first-line position in TNF-failures.

Although some novel biologic products, have amassed convincing efficacy data against anti-TNFs, their use will be limited to the anti-TNF failure patient population, at least in the mid-term. To progress up the treatment algorithm, new agents need to demonstrate superiority to anti-TNFs and show cost-effectiveness.

Reasons to Purchase

*Quantify the current size of rheumatoid arthritis sales in the seven major markets and understand trends in the Rest of World

*Assess the commercial opportunities for non-anti-TNF biologic products including Orencia, Rituxan/MabThera, Actemra, ocrelizumab and ofatumumab

*Detailed case studies analysing Simponi's product positioning and epidemiology-based assessment of biologic therapies by line and type of therapy

23-Dec-08 PDF & SlidePack & DataPack Pages 272

Table of Contents
Price: $15,200.00 / €10,159.68

BioPortfolio uses RBS Worldpay Secure Server for credit card transactions